MEDDIC, operated properly.
The dominant enterprise sales qualification framework — Metrics, Economic buyer, Decision criteria, Decision process, Identify pain, Champion. Created at PTC in 1996. Still the cleanest framework taught to enterprise AEs in 2026. But most teams operate it as a checklist filled in after the deal closes — which captures none of its real value. This is the opinionated deep-dive: what MEDDIC actually is, why champion is load-bearing, when to use MEDDPICC instead, and how modern signal-anchored selling sharpens every field.
01What MEDDIC actually is
MEDDIC is an acronym for the six qualification dimensions that a senior enterprise AE should be able to articulate on every deal above ~$25K ACV. The letters stand for:
- M — Metrics. The quantifiable economic outcome your solution drives for this customer. Not "improved efficiency" — actual numbers ("$340K saved annually" or "4-hour reduction in dbt build times").
- E — Economic buyer. The person who controls the budget and can override procurement. Often two layers above the champion. The person who signs.
- D — Decision criteria. The explicit + implicit criteria the buying team will use to choose between you and alternatives. Technical, commercial, political.
- D — Decision process. The path from current state to signed contract — every meeting, approval, security review, procurement cycle, board sign-off. Including the unwritten political steps.
- I — Identify pain. The specific operational pain your solution removes. Verified — not assumed from the champion's pitch. Quantifiable. Tied to a metric (the M).
- C — Champion. The internal advocate who pushes your deal forward when you're not in the room. Has personal pain the product solves, has political capital to spend, has a credible internal sponsor.
Each letter is both a question to answer ("who is the economic buyer?") and a field to fill in ("EB: Sarah Chen, CFO, joined Q3 2025"). The discipline is making sure all six are answered with confidence by stage 3 of the sales cycle — and red-flagging any that aren't.
The lineage
Created by Jack Napoli, Dick Dunkel, and John McMahon at PTC (Parametric Technology Corporation) in 1996. The framework was internal at PTC for over a decade — PTC's enterprise sales motion was so successful (compound 30%+ growth through the late 1990s) that the framework leaked into the broader enterprise software world through PTC alumni who became sales leaders at MongoDB, Snowflake, Cloudflare, Okta, and a dozen other enterprise companies.
By 2015, MEDDIC was the dominant qualification framework taught at enterprise sales bootcamps (Force Management, Winning by Design, Pavilion). By 2020, it was the default. In 2026 it remains the framework — but the way it's operated has drifted from its original intent in ways worth correcting.
02Why it became dominant (1996-2026)
MEDDIC won the qualification-framework wars for three reasons that are still true.
1. It's tuned for multi-stakeholder enterprise deals, not single-buyer SMB deals
The framework MEDDIC replaced was BANT (Budget, Authority, Need, Timing) — created at IBM in the 1960s for single-buyer mainframe sales. BANT assumes one person knows budget AND authority AND need AND timing. That model died around 2015 as enterprise deals shifted to 5-7 stakeholder buying committees. MEDDIC's six fields are structured to surface the multi-stakeholder reality: Economic buyer (different from champion), Decision process (multi-step, multi-meeting), Champion (the internal advocate). The fields map to the deal anatomy, not to a single conversation.
2. It surfaces hidden risk early
The most expensive deals are the ones that look great in stage 2 and die in stage 4 because of something the AE didn't know existed. MEDDIC's structure forces those unknowns to be named: "What's the Decision process? Who has to sign? When does procurement get involved?" An AE who can't answer those questions by stage 3 has a deal with hidden landmines. Forcing the question early — before forecasting commit, before exec involvement — saves the org from late-stage surprises.
3. It scales to deal review meetings
Sales managers running weekly deal reviews need a shared vocabulary for talking about pipeline. MEDDIC provides it. "What's the M on this deal?" "Have you met the EB?" "How's the champion?" Six standard questions that map across every deal in the pipeline. Without a shared framework, deal reviews devolve into anecdotes; with MEDDIC, they become structured triage.
03The 6 fields, in depth
The shallow version of MEDDIC is the letters. The operational version is what each letter actually demands of the AE and what questions surface the answer.
Notice how each field requires multi-source verification, not single-source belief. The champion can claim to be the economic buyer; you verify by asking three other stakeholders. The champion can claim the pain is huge; you verify by reading public signals, customer-voice mentions, and competitor analyst reports. MEDDIC fields are confirmed, not asserted.
04The 1 letter that does 60% of the work
Of the six MEDDIC fields, one is structurally load-bearing. The Champion is the single most predictive variable for deal outcome — more than ACV, more than industry, more than competitive intensity. Deals with an identified, met, validated champion close at 2-3x the rate of deals without one.
What a real champion is
A champion has three properties simultaneously. Miss any one and they're not a champion:
- Personal pain your product solves. Not company pain — personal pain. The champion themselves benefits when this deal closes (faster work, better data, less manual labor, exec credit for shipping). If the champion only benefits abstractly ("good for the company"), they won't fight for the deal when it stalls.
- Political capital to spend. Has been at the company long enough, performed well enough, and built enough relationships that other stakeholders will listen to them. New hires (under 6 months) usually lack the capital. Junior ICs usually lack the access.
- Credible internal sponsor. Reports to someone who would back them up in a budget fight. Without an internal sponsor at one level above, the champion is fighting alone — and most lose.
The test: would they sell this for free?
The cleanest diagnostic: would this person be selling the deal internally even if we weren't paying them, even if we weren't on the call? If yes, they're a champion. If no — if they're being nice but they wouldn't push the deal when nobody's watching — they're a friendly contact, which is something different and considerably weaker.
Champion absence is silent until it kills the deal
Most deals that die from "we decided to stay with our current vendor" or "the timing isn't right anymore" died because no real champion was selling internally when the AE wasn't there. The AE often doesn't realize there was no champion until they read the dead-deal postmortem. By then it's too late.
05The mistake every team makes
The single most common MEDDIC failure mode: operating it as a CRM checklist filled in after the deal closes, rather than a conversation guide that drives discovery.
Walk into 100 sales orgs that say they "use MEDDIC" and ~70 of them will show you a beautiful Salesforce dashboard with MEDDIC fields populated on every opportunity. Click into the field history and you'll see: blank, blank, blank, blank, all-fields-filled-in-one-day-the-day-after-closed-won.
That's not MEDDIC. That's CRM theater.
The real value of MEDDIC is the discovery conversation it forces. The fields aren't records to fill in; they're questions to answer in the deal itself. If you don't know who the economic buyer is by stage 3, MEDDIC tells you that fact — and tells you to find out before stage 4. If you don't have a verified champion, MEDDIC tells you that fact — and tells you to either identify one or downgrade the deal's forecast.
Stage 5: "Procurement is being a little tough but we'll get through it."
Closed-lost: "Customer decided to delay. We'll fill in MEDDIC fields for the postmortem."
The fields get filled in once. They never inform the work.
Stage 3: "Decision process unclear — security review timing unknown. Action: scoping call with InfoSec."
Stage 4: "Champion is solid but no backup. Action: thread to VP Engineering by EOQ."
Every field is either confirmed or blocking the next move.
How to fix it organizationally
Three changes a sales manager can make to shift the team from theater to operational use:
- Make MEDDIC fields required at stage transitions, not at close. Salesforce can enforce field validation on stage change. If the rep can't move a deal from stage 2 to stage 3 without a populated Economic Buyer field, the rep does the work to identify the EB — or honestly admits they don't know.
- Run deal reviews against MEDDIC, not against forecast. Instead of "what's your commit number this quarter," ask "what's the C on the Acme deal?" The conversation forces the rep to think in framework terms, not just dollar terms.
- Coach reps on the conversations, not the fields. The skill is asking the questions that surface MEDDIC answers — "If you wanted to push this through faster, who would you escalate to?" — not filling in the field after the fact. Sales coaching is conversation coaching; MEDDIC is the scaffolding.
06MEDDPICC and MEDDICC variants
MEDDIC evolved over its 30-year history. Two variants are worth knowing.
Which variant to use
Practical guidance: use the simplest variant that captures your deal complexity. Over-frameworking small deals creates rep frustration and field-fatigue. Under-frameworking large deals creates late-stage surprise.
- Under $25K ACV, single-buyer: Even MEDDIC is overkill. Use a lighter 3-field framework (pain, decision-maker, timeline) and save the energy.
- $25K-100K ACV, 2-4 stakeholders: Standard MEDDIC. The 6 fields scale to this deal size cleanly.
- $100K-$250K ACV, 3-7 stakeholders, competitive bake-off: MEDDICC. Adding the Competition field surfaces positioning risks that pure MEDDIC misses.
- $250K+ ACV, 5+ stakeholders, formal procurement: MEDDPICC. The Paper Process field is what keeps enterprise deals from slipping a quarter unexpectedly.
Most modern enterprise sales orgs default to MEDDPICC because the deal mix has shifted upmarket. Most mid-market and SMB-focused orgs stay on MEDDIC. Pick based on your ACV band, not based on what the latest book recommended.
07MEDDIC vs SPIN, Challenger, BANT, GAP
MEDDIC isn't the only qualification framework taught in B2B sales. The honest comparison:
The honest answer: most teams use multiple frameworks layered
The framing-war between MEDDIC vs Challenger vs GAP is mostly publishing-industry positioning. In practice, mature enterprise sales orgs use MEDDIC as the pipeline-management framework + SPIN or GAP as the discovery technique + Challenger as the pitch positioning. The frameworks operate at different layers; combining them isn't contradictory.
The exception is BANT — which is genuinely outdated for modern B2B and should probably be retired from most playbooks except inbound pre-qualification.
08How signals sharpen every MEDDIC field
The most-overlooked evolution in modern MEDDIC operation is what public buying signals do to the qualification process. Pre-signal-era, every MEDDIC field was answered through the champion's interview-elicited claims. In 2026, with mature signal-anchored data, every field can be cross-validated against public ground truth.
Metrics — sharpened by industry benchmarks
The champion claims "this saves us 40 hours per week." Without external reference, you have no way to validate. Public benchmarks (from glossary entries like reply rate, or industry analyst data) give you a calibration anchor. "Saves 40 hours per week" is plausible if the industry benchmark for your category is 25-60 hours; suspicious if it's 5-15 hours.
Economic buyer — sharpened by exec move signals
The champion says "the CFO Sarah signs deals like this." A signal-mining tool tells you Sarah joined as CFO 90 days ago, replacing the previous CFO who left after 4 years. That changes everything about how the EB will evaluate your deal — Sarah is making her first big budget decisions and will be more cautious than a 4-year veteran would be.
Decision criteria — sharpened by tech-stack data
The buying team's tech stack tells you what their unstated technical criteria are. A team running heavy Snowflake + dbt + Looker has implicit modern-data-stack alignment criteria they won't mention in discovery — but you can position against. Public tech-detection data (BuiltWith, Wappalyzer, Mama's tech-stack signals) makes these implicit criteria visible.
Decision process — sharpened by past procurement data
Past procurement timelines (visible via vendor case studies, past deal announcements, internal blog posts) reveal how this company actually buys. A company that announced a Snowflake deal 9 months after their first conversation tells you their procurement runs 9 months. The champion will tell you "we can move fast." The data tells you they can't.
Identify pain — sharpened by voice mining
The single biggest sharpening. The champion describes pain through their own framing — often softened to make their team look competent. Public voice mining (HN comments from their engineers, Reddit posts in industry subs, G2 review themes, conference Q&A) reveals the unfiltered version of their pain. "We've had some warehouse cost concerns" (champion's version) vs "we burned $200K in surprise Snowflake bills last quarter and the CFO is furious" (voice-mined version) — same pain, very different deal urgency.
Champion — sharpened by job-change signals
Your champion's career trajectory tells you about their political capital. A champion who's been at the company 18+ months in a stable role has accumulated capital. A champion in their first 60 days has none. A champion whose past two companies were acquired by your customer's competitors has different motivations than a champion whose past companies are happy customers of yours. Job-change signals reveal these patterns.
09Common mistakes that kill the framework
MEDDIC discovery is only as good as the data behind it.
Champion interviews give you the filtered version. Signal-anchored data gives you the ground truth. Mama surfaces the public signals — funding rounds, exec moves, tech changes, public voice — that let you cross-validate every MEDDIC field before the deal reaches stage 4. Start the free trial and run signal-anchored MEDDIC on your next 5 deals.